Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 89854M101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Readout Capital, LP
13G
|
5.4% |
9/25/2026
Event 9/21/2026
|
|
| Readout Capital, LP | 5.4% | ||
| Readout Capital GP, LLC | 5.4% | ||
| Matthew Smith | 5.4% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 4
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Biotechnology Value Fund L P | 5.7% | ||
| BVF I GP LLC | 5.7% | ||
| Biotechnology Value Fund II LP | 4.2% | ||
| BVF II GP LLC | 4.2% | ||
| Biotechnology Value Trading Fund OS LP | 0.1% | ||
| BVF Partners OS Ltd. | 0.1% | ||
| BVF GP Holdings LLC | 9.8% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 3
|
13.1% |
8/14/2026
Event 6/30/2026
|
|
| Lynx1 Capital Management LP | 13.1% | ||
| Weston Nichols | 13.1% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 3
|
10.0% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 5.4% | ||
| BVF I GP LLC | 5.4% | ||
| Biotechnology Value Fund II LP | 3.3% | ||
| BVF II GP LLC | 3.3% | ||
| Biotechnology Value Trading Fund OS LP | 1.0% | ||
| BVF Partners OS Ltd. | 1.0% | ||
| BVF GP Holdings LLC | 8.7% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 2
|
15.0% |
8/14/2025
Event 6/30/2025
|
|
| Lynx1 Capital Management LP | 15.0% | ||
| Weston Nichols | 15.0% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 3
|
2.5% |
8/12/2025
Event 6/30/2025
|
|
| Adage Capital Management, L.P. | 2.5% | ||
| Robert Atchinson | 2.5% | ||
| Phillip Gross | 2.5% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 1.8% |
7/16/2025
Event 6/30/2025
|
|
|
EcoR1 Capital, LLC
13G/A
Amendment 1
|
1.3% |
5/15/2025
Event 3/31/2025
|
|
| EcoR1 Capital, LLC | 1.3% | ||
| Oleg Nodelman | 1.3% | ||
| EcoR1 Capital Fund Qualified, L.P. | 1.2% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Biotechnology Value Fund L P | 6.4% | ||
| BVF I GP LLC | 6.4% | ||
| Biotechnology Value Fund II LP | 2.9% | ||
| BVF II GP LLC | 2.9% | ||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||
| BVF Partners OS Ltd. | 0.6% | ||
| BVF GP Holdings LLC | 9.2% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 5.4% |
4/24/2025
Event 3/31/2025
|
|
|
K2 HealthVentures Equity Trust LLC
13G/A
Amendment 3
|
6.9% |
2/14/2025
Event 12/31/2024
|
|
| K2 HealthVentures Equity Trust LLC | 6.9% | ||
| Parag Shah | 6.9% | ||
| Anup Arora | 6.9% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 1
|
10.9% |
2/14/2025
Event 12/31/2024
|
|
| Lynx1 Capital Management LP | 10.9% | ||
| Weston Nichols | 10.9% | ||
|
Adage Capital Partners GP, L.L.C.
13G/A
Amendment 2
|
7.1% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 7.1% | ||
| Adage Capital Partners GP, L.L.C. | 0% | ||
| Robert Atchinson | 7.1% | ||
| Phillip Gross | 7.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 61 | 36.3 M | $35.6 M |
| 2026 Q1 | 60 | 32.5 M | $32.8 M |
| 2025 Q4 | 62 | 30.7 M | $30.7 M |
| 2025 Q3 | 76 | 35.0 M | $63.7 M |
| 2025 Q2 | 84 | 35.8 M | $52.0 M |
| 2025 Q1 | 93 | 40.1 M | $55.4 M |
| 2024 Q4 | 91 | 41.5 M | $126 M |
| 2024 Q3 | 91 | 41.9 M | $208 M |
| 2024 Q2 | 84 | 41.7 M | $244 M |
| 2024 Q1 | 70 | 34.8 M | $276 M |
| 2023 Q4 | 58 | 32.2 M | $188 M |
| 2023 Q3 | 33 | 28.6 M | $73.2 M |
| 2023 Q2 | 30 | 28.0 M | $69.9 M |
| 2023 Q1 | 29 | 9.67 M | $20.3 M |
| 2022 Q4 | 30 | 9.53 M | $14.8 M |
| 2022 Q3 | 27 | 9.51 M | $29.0 M |
| 2022 Q2 | 25 | 9.68 M | $30.4 M |
| 2022 Q1 | 26 | 9.41 M | $26.3 M |
| 2021 Q4 | 30 | 9.86 M | $44.4 M |
| 2021 Q3 | 28 | 10.1 M | $83.5 M |